Our privacy policy describes how Fidessa uses cookies on our website. If you continue using our website, you are consenting to our use of cookies. OK

How was it for you?

I bumped into an old industry friend last week. We got talking about the state of the industry generally and agreed that everyone is having to take the whole concept of best execution a bit more seriously these days. Certainly in the UK the FCA has kicked off its “thematic review” and a number of fines are being doled out too. Best execution was the central plank in the original MiFID legislation, but has always been stymied by a lack of any universally agreed consolidated tape. What’s interesting now is that the FCA seems to be focussing on the actual outcome for clients rather than just insisting that firms maintain a documented best-ex policy. This is lifting the lid on exactly how tricky it is to best execute a client order, especially when you take into account volume discounts from exchanges, maker-taker rebates and concepts like asymmetric price slippage.

The real problem, however, still remains as the concept of best execution is all but meaningless to the man on the street. Putting the onus on the industry to show it performed well is one thing, but until the very end customer is empowered to question the executional prowess of the industry, best ex will remain as elusive as ever.

Leave a comment

Copyright © 2019 Fidessa Group Holdings Limited. All rights reserved.

The information contained within this website is provided for informational purposes only. Fidessa will use reasonable care to ensure that information is accurate at the time it is made available, and for the duration that it remains on the site. The information may be changed by Fidessa at any time without notice. We also reserve the right to close the website at any time. No representation or warranty, expressed or implied, is given on behalf of Fidessa or any of its respective directors, employees, agents, or advisers as to the accuracy or completeness of the information or opinions contained herein or its suitability for any purpose and, save in the case of fraud, all liability for direct, indirect, special, consequential or other loss or damages of whatever kind that may arise from use of the website is hereby excluded to the fullest extent permitted by law. Any decisions you make based on the information in this website are your sole responsibility and information on the website should not be relied upon in connection with any investment decision.

The copyright of this website belongs to Fidessa. All other intellectual property rights are reserved.

Fragulator® is a registered trademark of Fidessa Group Holdings Limited.

Reproduction or redistribution of this information is prohibited except with written permission from Fidessa.